The impact of COVID-19 on the global health system and economy will likely result in large-scale changes in zoonotic disease prevention preparedness.
Haymarket Medical Network, a part of business media company Haymarket Media, Inc., is proud to join the Ad Council’s first ever Private Marketplace (PMP) along with other partners Cadreon, The Trade Desk and Acxiom.
Exebacase is a novel, recombinantly-produced lysin (cell wall hydrolase enzyme), that targets the peptidoglycan cell wall.
The FDA has granted Orphan Drug designation to ARV-1801 (sodium fusidate; Arrevus) for the treatment of pulmonary exacerbations in patients with cystic fibrosis.
The FDA has granted Fast Track designation to RiVax® for the prevention of ricin intoxication.
The FDA has accepted for review a sNDA for Recarbrio™, to treat adult patients with hospital-acquired and ventilator-associated bacterial pneumonia.
The Food and Drug Administration has granted Fast Track designation to NanoFlu (Novavax) for seasonal influenza vaccination in adults ≥65 years.
Caroline O. Pardo, Ph.D., General Manager for Haymarket Medical Education, is pleased to announce that HME, based in Paramus, NJ, has been accredited as a provider of interprofessional continuing education by the Accreditation Council for Continuing Medical Education, the Accreditation Council for Pharmacy Education, and the American Nursing Credentialing Center.
The FDA has approved updated labeling for Epclusa, Harvoni and Vosevi to include updated information regarding treatment of patients with HCV who have severe renal impairment including those with end stage renal disease who are on dialysis.